NCT05302297View on ClinicalTrials.gov

Comparative Efficacy of Cemiplimab to Historical Standard of Care in France

CompletedOBSERVATIONAL
Enrollment

305

Participants

Timeline

Start Date

January 17, 2022

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Cancer/Squamous Cell Carcinoma of Skin
Interventions
DRUG

Cemiplimab

Pharmaceutical Form: Concentrate solution for injection for intravenous (IV) infusion Route of Administration: Intravenous (IV) infusion

Trial Locations (1)

Unknown

France

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY